Design Therapeutics, Inc. (DSGN): Shareholders' Equity
$212.50M
As of 2025-12-31
$201.86M
As of 2026-06-30
-13.4%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $212.50M | -12.2% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $242.10M | -12.8% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $277.69M | -15.2% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $327.31M | -14.3% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $382.13M | n/m | 2023-03-14, Balance as of period end |
| 2020-12-31 | -$11.31M | n/a | 2022-03-10, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Design Therapeutics, Inc. (DSGN) | 2025-12-31 | $212.50M | -12.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare DSGN, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗